HIV-1 env does not enable the development of protective broadly neutralizing antibodies is an experimental autoimmune encephalomyelitis mouse model

Published: 3 February 2022| Version 2 | DOI: 10.17632/8gfxch4kb9.2


DOI for this work is: 10.3389/fimmu.2021.771359 Published in 2021 by Lucia Lopalco et al. Recent studies showed that immunological tolerance may restrict the development of Env-specific autoreactive broadly neutralizing antibodies. This evidence is consistent with the finding that Env immunization of a systemic lupus erythematosus (SLE) murine model produced antibodies that neutralize tier 2 HIV-1 strains. In this study, we address the possibility of eliciting neutralizing anti-Env antibodies in other autoimmune diseases such as multiple sclerosis (MS). While, as reported for SLE, we showed for the first time that a small number of HIV-1 negative, relapsing remitting MS patients exhibited antibodies with neutralizing properties, our attempts at inducing those antibodies in a EAE mouse model of MS failed. The success in eliciting Env-specific neutralizing antibodies might be related to the specific characteristics of the autoimmune disease, or it might rely in improving the vaccination design. Studies using mouse models are useful to gain insight in how HIV-specific neutralizing antibody responses are regulated in order to develop a protective HIV-1 vaccine. The raw data of each figure reported in the manuscript is reported here. In total we have 6 different files.



Ospedale San Raffaele


Human Immunodeficiency Virus, Experimental Autoimmune Encephalomyelitis, Immunological Tolerance